{
  "docId": "019de077-58c2-77ec-8b05-6d27c4bb0498",
  "docSlug": "35a6e53e15f172ec3a7e4b1f473eaa42",
  "documentTitle": "Genprex | Investor Presentation Deck | 58 slides",
  "authorId": "genprex",
  "authorName": "Genprex",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2024-11-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 25,
  "pageCount": 58,
  "prevPage": 24,
  "nextPage": 26,
  "slideType": "traction",
  "function": "show_traction",
  "density": "dense",
  "nDataPoints": 6,
  "notes": "Kaplan-Meier survival curve showing PFS. Mentions Tecentriq as brand name for Atezolizumab.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de077-58c2-77ec-8b05-6d27c4bb0498/25",
  "deckHref": "/decks/019de077-58c2-77ec-8b05-6d27c4bb0498",
  "deckJsonHref": "/decks/019de077-58c2-77ec-8b05-6d27c4bb0498.json",
  "deckAnchorHref": "/decks/019de077-58c2-77ec-8b05-6d27c4bb0498#slide-25",
  "components": [
    {
      "bbox": {
        "h": 0.55,
        "w": 0.48,
        "x": 0.48,
        "y": 0.32
      },
      "kind": "chart",
      "text": "Kaplan-Meier curve for Progression-Free Survival",
      "attrs": null,
      "subkind": "line",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "01764922-fe54-46a0-a106-ab2ce9c775de",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.03,
        "w": 0.25,
        "x": 0.6,
        "y": 0.84
      },
      "kind": "disclaimer",
      "text": "Atezolizumab is the generic name of Tecentriq.",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "cfab4ec6-45d5-4e81-ba14-1935bdec0779",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.1,
        "w": 0.4,
        "x": 0.05,
        "y": 0.73
      },
      "kind": "list",
      "text": "PFS 2.6 vs 1.8 mos (HR 0.63)\nOS 12.5 vs 8.4 mos (HR 0.59)",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "3a36a0cc-a7ee-4b66-bd0b-8e5794f72e78",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.2,
        "w": 0.4,
        "x": 0.05,
        "y": 0.48
      },
      "kind": "list",
      "text": "Atezolizumab vs placebo\nAll CR, PR, and SD patients received maintenance therapy\nEndpoints measured from the start of maintenance therapy",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "422ea357-66b2-4ddc-815e-8f5a3d4f489f",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.1,
        "w": 0.4,
        "x": 0.05,
        "y": 0.33
      },
      "kind": "paragraph",
      "text": "Once patients begin maintenance therapy with Tecentriq, Progression Free Survival is very short (2.6 mos).",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "f7cb3fde-39c0-4f3e-bac8-7fc726bb4252",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.4,
        "x": 0.05,
        "y": 0.08
      },
      "kind": "title",
      "text": "Atezolizumab Maintenance Therapy",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "58c9efd1-3c71-4ba7-b052-05475daaf5b0",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [],
  "arcBeats": [
    {
      "to": 40,
      "from": 21,
      "beatId": "fba14042-e1cc-44ad-974d-c9a2c1f21ee2",
      "arcName": "Monroe's Motivated Sequence",
      "arcSlug": "monroes-sequence",
      "beatName": "Visualization",
      "beatSlug": "monroes-sequence-visualization",
      "evidence": "Future vision and potential impact of Genprex's gene therapies",
      "position": 3,
      "confidence": 0.8,
      "parentBeatName": "Evidence",
      "parentBeatSlug": "evidence"
    }
  ],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}